Analyst Emily Bodnar of H.C. Wainwright maintained a Buy rating on MiNK Therapeutics (INKT – Research Report), with a price target of $35.00.
Emily Bodnar’s rating is based on promising data from MiNK Therapeutics’ Phase 2 study of their iNKT cell therapy, agenT-797, in treating refractory gastroesophageal cancer (GEC). The study, which is led by a prominent oncologist at Memorial Sloan Kettering Cancer Center, has shown increased immune modulation, particularly in pro-inflammatory markers and T-cell activation, which are indicative of potential therapeutic activity.
While the study is still in its early phases and lacks control arm data, the observed increases in immune cell infiltration and cytokine activity suggest a positive response to the treatment. The comparison to historical data from the RAINBOW Phase 3 study provides a benchmark for efficacy, and the initial results are encouraging enough to warrant a Buy rating, pending further data on primary and secondary endpoints.